Abstract：ObjectiveTo study the changes of serum proprotein convertase subtilisin/kexin 9(PCSK9)levels in patients with coronary heart disease combined with chronic heart failure and its clinical significance.Methods45 patients who met the diagnostic requirements of coronary heart disease with chronic heart failure from January to August in 2016 of Internal Medicine-Cardiovascular Department in our hospital were selected as the case group.40 coronary heart disease patients without chronic heart failure were selected as the control group.The concentration of total cholesterol(TC), triglyceride(TG),low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C),PCSK9 and high sensitive C reaction protein(hsCRP)in the two groups were compared.All the patients were collected fasting blood 5 ml at the second day of admission and the case group were collected peripheral venous blood 5 ml after treatment to test the level of serum PCSK9 and hsCRP.ResultsThere was no significant difference in the level of TC,TG,LDL-C, HDL-C between the two groups(P＞0.05).The level of PCSK9 and hsCRP before treatment in the case group was significantly higher than that in the control group before treatment,with significant difference (P＜0.05).There was significant difference in the level of plasma PCSK9 and hsCRP before and after treatment in the case group(P＜0.05).There was no significant difference in the level of PCSK9 and hsCRP before and after treatment in the control group (P＞0.05).The levels of PCSK9 and hsCRP after treatment in the case group was lower than that in the control group after treatment, with significant difference(P＜0.05).ConclusionThe serum PCSK9 level is closely related to chronic heart failure,which may be involved in the pathogenesis of chronic heart failure by promoting inflammation,and can provide new ideas for clinical prediction and search for new treatment and intervention measures for chronic heart failure.
Stein EA，Swergold GD.Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics[J].Curr Atheroscler Rep，2013，15（3）：310.
[2]
Kosenko T，Golder M，Leblond G，et al.Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 （PCSK9）in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation[J].J Biol Chem，2013，288（12）：8279-8288.
[3]
Fang CH，Li JJ.Statin，like aspirin，should be given as early as possible in patients with acute coronary syndrome[J].Med Hypotheses，2005，64（1）：192-196.
[4]
Masahiro S，Keiko T，Naoki M.Effects of soluble TNF-alpha receptor 1 on apotosis induced by oxidized LDL in endothelial cells[J].Mol Cell Biochem，2004，258（1-2）：57-63.
[5]
Gullestad L，Ueland T，Vinge LE，et al.Inflammatory cytokines in heart failure：mediators and markers[J].Cardiology，2012，122（1）：23-35.
[6]
Cao S，Zeng Z，Wang X，et al.Pravastain slows the progression of heart failure by inhibiting the c-Jun N-terminal kinase-mediated intrnsic apoptic signaling pathway[J].Mol Med Rep，2013，8（4）：116-118.
[7]
Ridker PM，Rifai N，Clearfield M.Measurement of C-reactive protein for the targeting of station therapy in the primary provention of acute coronary events[J].N Engl J Med，2001，344（26）：1959-1965.
[8]
Wu CY，Tang ZH，Jiang ZS，et al.PCSK9-siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway[J].Mol Cell Biochem，2012，359 （1）：347-358.
Poirier S，Mayer G.The biology of PCSK9 from the endoplasmic reticulum to lysosomes：new and emerging therapeutics to control low-density lipoprotein cholesterol[J]. Drug Des Devel Ther，2013，7：1135-1148.
[13]
Shen L，Peng H，Xu D，et al.The next generation of novel low-density lipoprotein cholesterol-lowering agents：proprotein convertase subtilisin/kexin 9 inhibitors[J].Pharmacol Res，2013，73（7）：27-34.
[14]
Tang Z，Jiang L，Peng J，et al.PCSK9 small interfering RNA（siRNA）suppresses the oxLDL-induced inflammatory cytokine expression in THP-1-derived macrophages[J].Int J Mol Med，2012，30（4）：931-938.
京公网安备 11010502046607号